Johnson & Johnson diabetes drug tops older therapies in studies
(Reuters) – An experimental treatment for type 2 diabetes developed by Johnson & Johnson demonstrated greater reduction in blood sugar than Merck & Co’s Januvia and an older common treatment, glimepiride, according to data from a pair of late stage clinical trials. The J&J drug, canagliflozin, also led to significantly greater weight loss than both of the other drugs and far fewer incidents of hypoglycemia, or potentially dangerous drops in blood sugar levels, than glimepiride, a member of the sulfonylurea class of medicines. …